VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture: MBI), a life science company focused on the development and commercialization of genomic-based diagnostic tests for cancer and cardiovascular disease, is pleased to announce that Dennis L. Grimaud has joined the company’s Board of Directors.

Mr. Grimaud, Chief Executive Officer of Theragnostix Reference Laboratories Inc., an innovative clinical laboratory providing diagnostic services for infectious disease, has over 30 years of experience in the health care industry and 18 years of experience in biotechnology and molecular diagnostics as an entrepreneur, senior executive and consultant.

"Dennis has a proven track record of diagnostics leadership and brings to Med BioGene significant industry contacts and valuable experience in managing high-growth life science companies, commercializing molecular diagnostics tests and creating substantial shareholder value through product development and alliances.  We are very pleased to welcome him to our team" commented Erinn Broshko, Chief Executive Officer of MBI.

From 2004 to 2006, Mr. Grimaud was the Chief Executive Officer of Genaco Biomedical Products, Inc., a molecular diagnostics company with proprietary multiplexing technology for infectious disease and cancer diagnostics.  In 2006, Mr. Grimaud led the sale of Genaco to global molecular diagnostics leader Qiagen (Nasdaq: QGEN).  Theragnostix is in the process of licensing this technology from Qiagen.

Previously, Mr. Grimaud founded Cytometry Associates in 1988 and served as its President and Chief Executive Officer until 1999. A company providing cancer diagnostic, drug discovery and clinical trial services, Cytometry Associates was recognized as one of the Top 50 Fastest Growing businesses in the area. Mr. Grimaud has held other prominent leadership roles in the health care, biotechnology and banking industries.

"I am delighted to join Med BioGene at such an exciting time in the company’s growth," stated Mr. Grimaud.  "Med BioGene is well-positioned to be an up-and-coming leader in the development and commercialization of genomic diagnostic tests.  It has an impressive and focused management team and solid intellectual property assets and collaborations, particularly in the development of its lymphoma diagnostic array, LymphExpress DxTM.  I look forward to working with the other board members and management to make Med BioGene a success."

Corporate Matters

MBI has granted five-year incentive stock options to purchase an aggregate of 150,000 common shares at an exercise price of $0.34 per share.

About Med BioGene

MBI is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer and cardiovascular disease.  MBI develops these tests by identifying the genes, known as "biomarkers," which indicate the presence of disease.  The development of these tests is the first step towards personalized medicine and will replace the conventional "one drug fits all" approach to disease management.

MBI is currently developing tests for lymphoma, leukemia and cardiovascular disease through the following products:  LymphExpress DxTM, LeukExpress DxTM and CardioExpress DxTM.

For corporate information, please contact:

Erinn B. Broshko
Chief Executive Officer
(604) 306-4969
ebroshko@medbiogene.com
www.medbiogene.com

For investor relations information, please contact:

The Howard Group Inc.
(888) 221-0915
info@howardgroupinc.com
www.howardgroupinc.com

or

Peterson Capital
(604) 684-2883
rick@rickpeterson.ca
www.petersoncapital.ca 

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation.  Words such as "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "will", "would" and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but is not limited to, that with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. This forward-looking information is only a prediction based upon MBI’s current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and is based on uncertain assumptions that could cause MBI’s actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. MBI’s forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.